Highlights

• Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, ⁶⁴Cu-SAR-bisPSMA was found to be safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR).
• In trial participants where standard of care (SOC) imaging was unable to detect any lesions, up to approximately 60% had lesions identified by same-day imaging with ⁶⁴Cu-SAR-bisPSMA and up to 80% on next-day imaging, with high specificity on both days. The number of lesions identified by ⁶⁴Cu-SAR-bisPSMA almost doubled from same-day (up to 80) to next-day imaging (up to 153).
• One of the reasons for the higher detection of lesions on next-day imaging was due to the ability of ⁶⁴Cu-SAR-bisPSMA to detect much smaller lesions compared to other prostate specific membrane antigen (PSMA) agents, including a lesion with a diameter of less than 2 mm.
• For all lesions, regardless of their size, ⁶⁴Cu-SAR-bisPSMA lesion uptake increased by more than 80% and lesion contrast increased almost 5 times when comparing same-day to next-day imaging.
• A key observation was the high uptake and contrast observed in lesions of less than 5 mm.
• More lesions and smaller lesions detected on next-day imaging could have a substantial impact on how patients are treated.
• The detection of lesions that are less than 5 mm in size by current PSMA positron emission tomography (PET) imaging agents (including PYLARIFY^® and the generic product ⁶⁸Ga-PSMA-11) is challenging, which possibly contributes to the low sensitivity of these agents.
• The information gathered from the Phase 1/2 COBRA trial, including the size of lesions that are detected by ⁶⁴Cu-SAR-bisPSMA, will be used to inform the design of the registrational Phase 3 trial in patients with BCR of PC.

SYDNEY, March 8, 2024 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to share additional data from its diagnostic ⁶⁴Cu-SAR-bisPSMA trial, COBRA (NCT05249127)^[1].

COBRA was a multi-centre, single-arm, non-randomised, Phase 1/2 diagnostic imaging study of ⁶⁴Cu-SAR-bisPSMA administered to participants with BCR of PC following definitive therapy and who had a negative or equivocal SOC scan at screening. The primary objectives of the trial were to investigate the safety and tolerability of ⁶⁴Cu-SAR-bisPSMA as well as its ability to correctly detect recurrence of PC. Patients underwent PET/computed tomography (CT) scans with ⁶⁴Cu-SAR-bisPSMA on Day 0 and Day 1 (1-4h and 24±6h post-dose, respectively), which were interpreted by three blinded central readers. Following the recent announcement of positive results from the COBRA trial^[2], which began showcasing the many benefits of ⁶⁴Cu-SAR-bisPSMA, further analysis of the data reveals additional advantages of this optimised PSMA product.

⁶⁴Cu-SAR-bisPSMA was able to detect much smaller lesions than anticipated, including a lesion with a diameter of less than 2 mm. This compares favourably against the current SOC PSMA PET imaging agents, including PYLARIFY^® and the generic product ⁶⁸Ga-PSMA-11, with which the detection of lesions smaller than 5 mm is challenging. Sensitivity is a known challenge for the existing PSMA PET agents, particularly for lesions <5 mm^[3]-[6]. This suggests that lesions are missed by current SOC imaging, which can have significant implications on accurate staging and subsequent treatment decisions. For those undergoing initial staging of their disease, missing lesions may lead to unnecessary surgery resulting in long-lasting side effects (e.g. impotence and/or incontinence following the removal of the prostate)^[7]. In patients with BCR of PC, it is also crucial to identify their cancer early to avoid disease progression and the side effects of systemic treatments that accompany such therapies^[8].

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “The cornerstone of better therapy is better diagnosis, and we are incredibly excited about the substantial degree of improvement in detection of lesions with our bisPSMA product compared to SOC imaging. This difference is similar to comparing the old Hubble telescope to the new James Webb telescope, allowing us to visualise with much greater clarity, and to effectively change the paradigm of treatment to considerably improve the outcomes for patients with PC. Innovative products like ⁶⁴Cu-SAR-bisPSMA may prevent many millions of men from receiving inappropriate treatments and suffering substantial debilitating side effects from surgery or other therapies.

“When combining the optimised dual PSMA targeting agent with the ideal half-life of copper-64 (⁶⁴Cu), we continue to observe higher uptake and retention of ⁶⁴Cu-SAR-bisPSMA in PC lesions. We believe the ability of ⁶⁴Cu-SAR-bisPSMA to detect such small lesions is due to the higher uptake and retention of the product over time with high contrast (parameters measured by mean standardised uptake value [SUVmean], maximum standardised uptake value [SUVmax] and tumour-to-background ratio [TBR]). Small lesions become more readily detectable if the uptake of the product in the lesion is high and the background noise on the image is low. This effect enhances the contrast, making the lesion easier to detect, providing clinicians with valuable information on how to best treat their patients.”

The size of the PC lesions detected by ⁶⁴Cu-SAR-bisPSMA was recorded on the same-day (Day 0) and next-day (Day 1) imaging. Lesions with less than 5 mm in size were identified across readers among 14% (7/50) of patients (Figures 1 and 2). These lesions were located in the bone, pelvic and extra-pelvic lymph node regions. The smallest lesion (pelvic lymph node) identified in the study was 2.6 x 1.9 mm (Figure 3).

The SUVmax, SUVmean and TBR were assessed in up to 25 lesions per patient on the same-day and next-day ⁶⁴Cu-SAR-bisPSMA PET imaging. Mean SUVmean and SUVmax increased more than 80% (82% and 87% average increase across all readers, respectively) and TBR increased almost 5 times (4.8x average increase across all readers) comparing same-day with next-day imaging (ranges among readers, Day 0 and Day 1, respectively: SUVmean 6.6-9.9 and 14.7-15.8; SUVmax 13.9-14.0 and 22.2-33.4; TBR 23.2-25.4 and 118.1-181.7) (Graphs 1 and 2). Lesions of less than 5 mm in size had SUVmean, SUVmax and TBR value of 16.3, 16.8 and 90.1, respectively (mean values across all readers).

The ability of ⁶⁴Cu-SAR-bisPSMA to detect lesions less than 5 mm is a result of a few factors unique to the product. ⁶⁴Cu has a longer half-life (12.7 h) than the isotopes used in currently approved PSMA PET agents, such as gallium-68 (⁶⁸Ga) and fluorine-18 (¹⁸F) (<2 h), enabling next-day imaging, which is impossible with ¹⁸F- and ⁶⁸Ga-based agents. Clarity’s SAR Technology holds isotopes of copper securely inside a cage, preventing their leakage when administered to patients. Pre-clinical and clinical evidence has demonstrated that the optimised dual targeting molecule connected to the cage, bisPSMA, ensures increased targeting and retention of the product in PC tumours compared to its single targeting molecule counterpart and approved PSMA agents^[9],[10]. Results from Clarity’s Phase I PROPELLER trial substantiated this hypothesis as ⁶⁴Cu-SAR-bisPSMA showed detection of additional lesions and 2-3 times greater uptake within the same PC lesions compared to the generic SOC imaging agent, ⁶⁸Ga-PSMA-11. Furthermore, the initial positive results from the COBRA study, announced on the 15^th of February 2024^[2], showed that delayed imaging with ⁶⁴Cu-SAR-bisPSMA is able to detect PC lesions in up to 80% of patients with BCR of PC, who demonstrated negative or equivocal SOC imaging at screening. It also showed that the number of lesions detected by ⁶⁴Cu-SAR-bisPSMA almost doubled on delayed imaging compared to same-day imaging.

“The COBRA trial was designed to showcase the true benefits of bisPSMA compared to current SOC imaging, implementing a high standard of study design to validate our findings and utilise an unbiased view of assessment. The results are nothing short of extraordinary, and as we continue to adhere to best practice in clinical development, our science at Clarity is clearly differentiating us from our competitors. Combined with our clinical and pre-clinical evidence to date, this data further validates SAR-bisPSMA as a potential best-in-class PSMA agent for the diagnosis (with ⁶⁴Cu) and subsequent treatment (with copper-67 [⁶⁷Cu]) of PC. The benefits of ⁶⁴Cu-SAR-bisPSMA are now even more evident, given the highest scientific rigour applied to the COBRA study design, and confirmed by clinicians who reported that they would change their treatment plan in response to the ⁶⁴Cu-SAR-bisPSMA scan results in approximately half of their trial patients. Our COBRA trial was an exploratory first-in-human Phase 1/2 trial in BCR to generate information to allow us to meticulously design a Phase 3 registrational trial. Now that we know what we are looking for, including lesions in the 2 mm range, we can structure a Phase 3 trial in the BCR of PC indication to clearly differentiate ourselves from the first-generation PSMA agents as we head towards our ultimate goal of improving treatment outcomes for people with cancer,” Dr Taylor said.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) Technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR Technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁴Cu-SAR-bisPSMA and ⁶⁷Cu-SAR-bisPSMA are unregistered products. The data outlined in this announcement has not been assessed by health authorities such as the US Food and Drug Administration (FDA). A clinical development program is currently underway to assess the efficacy and safety of these products. There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death worldwide^[11]. The American Cancer Institute estimates in 2024 there will be 299,310 new cases of prostate cancer in the US and around 35,250 deaths from the disease^[12].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com

References

1. Clinicaltrials.gov Identifier: NCT05249127. clinicaltrials.gov/ct2/show/NCT05249127
2. Initial COBRA results announcement. 15 Feb 2024. claritypharmaceuticals.com/news/cobra_results/
3. Pienta et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸F-DCFPyL in Prostate Cancer Patients (OSPREY). Journal of Urology, 2021.
4. Hope et al. Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncol, 2021.
5. Petersen et al. ⁶⁸Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. World Journal of Urology, 2019.
6. Surasi et al. Diagnostic Performance and Safety of Positron Emission Tomography with ¹⁸F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). European Urology, 2023.
7. Stanford et al. Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate Cancer. The Prostate Cancer Outcomes Study. JAMA, 2000.
8. Shore et al. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer and Prostatic Diseases, 2023.
9. Zia et al. A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. Angew Chem Int Ed Engl. 2019.
10. Lengyelova et al. ⁶⁴Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer. ASCO, 2023.
11. Global Cancer Statistics 2020. GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
12. American Cancer Society Key Statistics for Prostate Cancer. cancer.org/cancer/prostate-cancer/about/key-statistics.html 

This announcement has been authorised for release by the Executive Chairperson.

Source

SEOUL, South Korea, March 8, 2024 /PRNewswire/ — Wellysis, a digital healthcare company spun off from Samsung, has announced the launch of remote cardiac monitoring service in the US in partnership with Artella Solutions (ARTELLA).

This collaboration builds on its FDA-cleared S-Patch electrocardiogram monitoring solution, now featuring the newly FDA-cleared S-Patch ExL device. The ExL model allows for extended testing periods of about 14 days on a single coin battery and received FDA clearance in early February. With this milestone, Wellysis can now expand its reach in the Extended Holter service and Mobile Cardiac Telemetry (MCT) service.

Wellysis is introducing its S-Patch ExL solution to US patients thorough a partnership with ARTELLA, headquartered in Houston, Texas. ARTELLA provides comprehensive remote cardiac monitoring solution across 10 states. By teaming up, Wellysis and ARTELLA aim to deliver an unparalleled end-to-end cardiac monitoring service, commencing in Texas.

The newly launched program includes bundling of Samsung smartphones and smartwatches, seamlessly integrating with the S-Patch ExL device.

Wellysis CEO Young Juhn expressed excitement about this milestone collaboration, stating, “We are thrilled to partner with ARTELLA for our remote cardiac monitoring service in the US, introducing this end-to-end solution using S-Patch to US patients. This collaboration signifies the beginning of an exciting journey, with plans to integrate AI algorithms soon.”

Sepand Moshiri, Co-Founder and CEO of ARTELLA, commented, “This organic journey has led to a dynamic partnership with Wellysis, combining forces to redefine the future of patient care. Together, we are at the forefront of cardiac monitoring innovation, harnessing the power of artificial intelligence and virtual real-time monitoring.”

The groundbreaking collaboration will be unveiled at the upcoming American College of Cardiology (ACC) meeting in April.

In addition to this launch, Wellysis is actively working on obtaining FDA clearance for its AI algorithms, further cementing its commitment to innovation and advancing patient care.

About Artella Solutions Inc.

Artella Solutions Inc. is a forward-thinking digital health care company monitoring patients’ heart rhythms and assisting physicians’ paths from care to cure using the latest patch technology and artificial intelligence to detect and capture abnormal changes in heart rhythms.

The company provides health care providers with one system that meets their real-time diagnostic data needs for immediate viewing while advancing the well-being of their patients with heart rhythm disorders to ensure best clinical outcomes and economic benefits. To learn more, visit artellainc.com

About Wellysis

Wellysis is a digital healthcare company dedicated to revolutionizing patient care through innovative ECG monitoring solutions. The company was founded in 2019 as a spin-off from Samsung SDS’s Digital Health division by a team of experts with extensive experience in the healthcare field. Its flagship product, S-Patch, is a user-friendly, wearable ECG monitor that provides real-time data and advanced analysis, empowering clinicians and patients alike. The company has successfully expanded its business to overseas markets, with over 790 hospitals and clinics using the product worldwide.

Source

MACAU, March 8, 2024 /PRNewswire/ — Artelli, the pioneering multi-dimensional art space, joined hands with ARTONEERS and Caelis Galeria to host the opening ceremony of new exhibition on March 7(Yesterday). Renowned New York artist Adam Handler traveled to Macau to attend his first solo exhibition in Macau, titled “Always near you…Always”, marking his largest solo exhibition in Asia to date. With the arrival of ART MARCH, Artelli has announced a series of outreach events. These events aim to offer a diverse art experience to the public, leveraging Artelli’s role as a platform that connects international artists with the local art community in Macau. These events also provide an open space for art enthusiasts to gather, interact, and enrich the local cultural scene through the appreciation and interaction with artworks.

Ms. Linwood Lin, Chief Innovation Officer of Forward Fashion Group and Artelli, expressed, “Artelli is dedicated to establishing itself as a pioneering art brand in Asia. Since its inception over a year ago, Artelli has partnered with international artists from the United States, the United Kingdom, Japan, and other regions to curate international original art projects and invite artists to visit Macau for close interactions with the public. Artelli will continue to expand the art business ecosystem and host outreach activities such as art education and art therapy to provide diverse art experiences. We will also continue to promote art accessibility and leverage Macau’s unique platform to attract international travelers, encouraging them to explore ‘Travel’ and ‘Art’ itineraries, further bolstering Macau’s reputation as a cultural hub.”

Mr. Jose Ignacio Ruiz Caparros, Co-founder of Caelis Galeria and ARTONEERS, shared, “Macau is a place where diverse cultures converge, and we are delighted to collaborate with Artelli to present the largest exhibition of New York artist Adam Handler in Asia. Most of the works in this exhibition were created specifically for this occasion. Before coming to Macau, it was difficult to imagine a multi-dimensional art space like Artelli. During the preparation period, we learned about the city’s emphasis on art development and its potential. Collaborating with the Macau team for the first time has shown us their international perspective and execution capabilities. We hope to bring more art projects to Macau in the future.”

Global Debut of Original Artwork Featuring Large-Scale Art Installations

This exhibition, themed “Love Heals” showcases Adam Handler’s new and debut creations, including the Ghost Series, the UFO Abduction Series and the Battle Ground Series. Handler captivates audiences worldwide with his distinctive Kawaii Faux Naïf style, which seamlessly blends whimsy and therapeutical elements. Using acrylic paint, oil stick, pencil, and markers, Adam Handler employs a passionate and childlike drawing technique to create unique outlined characters that almost appear flat, lacking depth. Artelli’s two levels feature large-scale art installations, enhancing the overall exhibition with a richer visual effect.

Handler often translates his personal experiences and emotions into phrases in his works. Elements of Handler’s studio in New York have been brought into the exhibition venue to let the audience understand the artist’s creative thinking and current thoughts from his perspective. Elements of Handler’s New York studio been brought into the exhibition venue to allow visitors to understand the artist’s creative thinking and current thoughts from his point of view. A message board inspired by one of the artist’s most iconic characters, “Ghost”, is also available in the exhibition venue. The audience can leave a unique phrase or share thoughts after viewing the exhibition in the “Soul Room”, as a way to share the world of each other’s souls with the artists.

At the opening ceremony, Artist Adam Handler said, “Each of the works in this exhibition reflects my heart and soul, containing deep emotions and stories, but also to express the desire for love and healing. Macau is a wonderful place, and it is an honor to meet my familiar collectors and new friends in person. Thank you to Artelli, ARTONEERS and Caelis Galeria for making this my largest solo exhibition in Asia, and I am very happy to be able to present the characters in my head in the form of a large-scale art installation, which is one of my favorite exhibitions in my personal art career. “

Download High Resolution Photos: https://pan.baidu.com/s/116kuKLFtenXD_pq_uTHO5w?pwd=85m9 Password: 85m9

Adam Handler’s Macao Debut Exhibition “Always near you…Always”

Follow Artelli’s official platform to get the latest information.

About Artelli

Artelli is the pioneering multi-dimensional space for contemporary art, lifestyle aesthetics, digital and techno art, art communities, and brand collaborations. The space stands as a new and unprecedented international landmark for art and culture.

Artelli will ultimately join forces with over a hundred internationally renowned artists and brand designers to co-create exclusive art projects and debut collections. With a dedicated focus on Web 3.0 digital art and metaverse, Artelli pioneers the exploration of new artistic dimensions. Guided by a strong commitment to become a multi-dimensional art space that fosters collaborations within the art and culture communities, Artelli’s visionary path unfolds through the fusion of art, technology, and the dynamic commercial sector.

Artelli has successfully organised more than five highly anticipated art exhibitions, featuring international artists in prime locations spanning Macau, Hong Kong, Taipei, and Shanghai. In the future, Artelli envisions expanding its brand to attain international prominence as the landmark for art and culture. With aspirations reaching Tokyo, Seoul, Singapore, New York, London, and Paris, Artelli is set to leave a vivid mark on the global stage over the next five years.

About ARTONEERS

ARTONEERS Hong Kong is an art commercialization brand created by Caelis Galeria and pH7 Communications CO.. ARTONEERS is a representative product of the combination of “ART” and “PIONEERS”, where “ART ” represents the creative presentation of artists, and “PIONEERS” represents pioneers who open and explore new fields. Therefore, we coined the term “ARTONEER” (Art Pioneer) to describe the innovative and pioneering spirit of artists and their imaginative works. Aiming to be a bridge linking art, business, society and people, Art Frontier Hong Kong has its own branded art gallery, exclusive artist representation, commercial art co-operation planning and execution, art derivatives production and other art-related services. We also aim to realize the double-track enhancement of the artistic and commercial value of our artists.

About Caelis Galeria

Founded in 2014, Caelis Galeria is an avant-garde contemporary art gallery based in Shanghai, nestled within the vibrant M50 Cultural Park. Housed in a stylish and architecturally impressive space, the gallery provides a dynamic platform for emerging and established artists to showcase their avant-garde creations. Caelis Galeria is a symbol of innovation, providing a haven for those wishing to explore the ever-evolving nature of contemporary art. With its commitment to expanding the boundaries of the art world and providing a platform for a plurality of voices, the gallery continues to be an important driving force in shaping the narrative of contemporary culture!

About Forward Fashion (International) Holdings Company Limited

Forward Fashion (International) Holdings Company Limited is an integrated group with three synergistic business segments – fashion, art, and lifestyle – and a commitment to creating innovative retail business model. With a track record of managing over 100 brands, the Group has helped many brands to establish their first presence in Greater China. In recent years, the Group has actively enhanced its operations and developed its own brands, such as Artelli, ASCE, UMJ, WF Fashion, to further enrich its brand portfolio. Leveraging its extensive retail experience and IP resources, the Group has spearheaded exclusive collaborations with brands and cultural and art communities to expand into the international market. In January 2024, the Galeries Lafayette Macau, introduces and operates by Forward Fashion, officially opened as an anchor tenant of the YOHO Treasure Island Resorts World Shopping Centre.

Mr. Fan Wing Ting, Patrick, is the founder, chairman and executive director of Forward Fashion Holdings. In 2005, he founded the first company of the Group in Hong Kong focusing on fashion apparel retail in Greater China. Following the Group’s 2020 listing on the Main Board of The Stock Exchange of Hong Kong Limited, Forward Fashion has embarked on eCommerce platforms and introduced international fashion and artistic brands and visionary international art projects to Greater China. The Group aims to cater for the preferences and needs of local youths and promotes business diversification.

Source

A three-day event highlighting the diversity of Macao’s ‘tourism+’ initiatives and Sands Resorts Macao’s comprehensive integrated resorts offerings 

MACAO, March 8, 2024 /PRNewswire/ — Sands^® Resorts Macao is participating in the ‘Experience Macao‘ Mega Roadshow in Tokyo, Japan from March 8-10, organised by the Macao Government Tourism Office (MGTO). The informative three-day event shines a spotlight on the MGTO’s varied ‘tourism+’ initiatives as part of its ongoing strategy to expand the diversity of travellers for a more robust recovery of the tourism economy. 

The key goal of the roadshow is to stimulate interest in Macao as a preferred leisure and MICE destination. This includes hosting a travel trade seminar and deepening visitors’ knowledge of Macao through a range of appealing activities and enticing offers for both business and leisure travellers.

Dr. DeVonne Iao, Senior Vice President and Chief Marketing Officer of Sands China Ltd. said, “We are delighted to participate in the ‘Experience Macao‘ Mega Roadshow organised by the MGTO in Tokyo, Japan. This opportunity allows us to introduce the rich offerings of Sands Resorts Macao, and Sands Lifestyle’s unique experiences, to its residents, tourists and industry professionals. We aim to continuously raise Macao’s profile as a ‘World Centre of Tourism and Leisure’. Our participation is a demonstration of Sands China’s firm commitment to support the MGTO’s ‘tourism+’ initiatives and its ongoing efforts to develop a full spectrum of diversified tourism offerings.”

The company’s participation is also aligned with its ongoing efforts to explore creative ways to develop closer cultural ties with Japan, such as the inaugural 2024 Macau Japan Spring Festival, taking place at Sands Resorts Macao until the end of March.

At the Mega Roadshow, Sands Resorts Macao, comprising three interconnected integrated resorts, The Venetian^® Macao, The Parisian Macao and The Londoner^® Macao, is highlighting its Michelin-starred and award-winning restaurants, world-class accommodation, duty-free shopping, extensive MICE facilities, and engaging leisure and entertainment options. It is also promoting one of its popular accommodation packages, the Stay 2 Nights and Get Special Offer, which will provide guests from Japan with an unforgettable experience of Sands Resorts Macao. 

Visitors to Sands Resorts Macao’s striking booth are sure to be captivated by the design homage it pays to the European signatures of each integrated resort, including photo and Instagram hotspots – Elizabeth Tower (Big Ben), the Eiffel Tower and the iconic Venetian gondola. They can also enjoy travel experience videos that showcase the myriad of ways to stay, shop, dine and be entertained at Sands Resorts Macao.

For more information, visit https://en.sandsresortsmacao.com/ or the official Facebook accounts of Sands Lifestyle, Venetian Macao, Parisian Macao, Londoner Macao, Conrad Macao and Sands Macao.

Source

AXA and Chiron Medical join hands to introduce Hong Kong’s first women-exclusive health centre
Comprehensive care for women’s health with an entire female medical team at the helm

HONG KONG, March 8, 2024 /PRNewswire/ — Commemorating International Women’s Day on 8 March, AXA Hong Kong and Macau (“AXA”) and Chiron Medical Group (“Chiron Medical”) jointly announced the grand opening of the “AXA Women’s Health Centre” (The Centre). It marks the first collaboration of its kind between an insurance company and a medical service group in Hong Kong. The Centre is designed to meet women’s unique needs, providing comfortable and attentive one-stop health management services, covering examination, diagnosis, treatment, and health management.

Women in Hong Kong play important roles in society, the workplace, and at home. Amidst balancing their responsibilities and striving for excellence, they tend to overlook their health by skipping routine check-ups and failing to respond to concerning symptoms in their bodies. Government statistics indicate a rising trend in newly diagnosed cancer cases among women, surpassing men for the first time in 2020^[1]. This highlights the urgent need for society to address women’s health challenges, calling for collaborative efforts to raise women’s awareness about preventative healthcare, regular check-ups, and the value of healthy living.

To promote early diagnosis and timely treatment for women, AXA has partnered with FemWell, a female health brand owned by Chiron Medical, to launch the “AXA Women’s Health Centre” in the bustling heart of Tsim Sha Tsui. This cutting-edge facility provides a full range of women’s health services, including general practice, obstetrics and gynaecology, clinical oncology, general surgery, and consultations with clinical psychologists, psychiatrists, nutritionists, and chiropractors, all overseen by a female medical team. A professional case manager will be assigned to follow up on individual needs, from organising appointments and examinations to administering treatment and rehabilitation care, assuring continuous assistance throughout the process.

The “AXA Women’s Health Centre” breaks away from traditional clinic styles and places a strong emphasis on being “thoughtful, friendly and reliable”. The Centre’s inviting and soothing interior creates a comfortable and reassuring environment for visitors, reducing their nervousness or anxiety during medical visits. The dedicated changing rooms, exclusive waiting areas, consulting rooms and imaging screening rooms ensure high privacy and comfort during the examination and consultation procedures.  

Emily Li, Chief Employee Benefits and Wellness Officer at AXA Hong Kong and Macau, said, “I am excited to the official launch of the ‘AXA Women’s Health Centre’ in partnership with FemWell, a female health brand under Chiron Medical, in celebration of today’s International Women’s Day. This initiative aims to raise awareness of women’s health and provide more comfortable, high-quality services tailored to their unique needs. AXA has always remained our commitment to supporting women’s health. Last year, we successfully introduced the innovative ‘Better She’ health management programme^[2] in Hong Kong, specifically designed for women. This programme integrates gynaecological services and preventive treatment from both Traditional Chinese and Western medicines to improve women’s physical and mental well-being, thereby reducing the risk of critical gynecological disease in the future. The opening of the Centre for today marks another significant milestone in our dedication to women’s health. Leveraging the strengths of AXA and Chiron Medical, we provide comprehensive medical and holistic healthcare to women throughout their health journey, empowering them to prioritise early prevention, early detection, and early treatment.”

Wallace Wong, Managing Director at Chiron Medical Group, said, “I’m honoured to announce the launch of the Centre today through the partnership with AXA and our FemWell, the female health brand under Chiron Medical. With our group’s “people-oriented” philosophy at the core, FemWell takes a comprehensive approach to support women’s health, guided by a team of female experts. The Centre adheres to “Illness treatment” and “Wellness management” principles while embracing a refreshing concept of ultimate comfort. Placing our customers’ health at the forefront, we provide personalised health experiences that cater to women’s unique needs. As the first phase of FemWell’s development under Chiron Medical, the Centre represents a significant milestone. We will actively explore further collaborations that share our vision of promoting women’s holistic well-being within the healthcare ecosystem. Our goal is to take a customer-driven approach to deliver mental and physical health services and more educational resources, empowering women to proactively improve their overall well-being.”

AXA has always been dedicated to meeting customer needs and adapting to market dynamics. We continuously invest resources and foster partnerships to strengthen our extensive medical and specialty medical network. Building on the success of the “AXA Medical Centre” and the “AXA Designated Endoscopy and Day Surgery Centre, the launch of the “AXA Women’s Health Centre” expands our network to cater specially to women’s healthcare needs through our collaboration with FemWell, a female health brand owned by Chiron Medical.  By championing a new and empowering approach to comprehensive women’s healthcare, AXA supports women’s health across Hong Kong while demonstrating our commitment to lifelong partnership with our customers.

At the AXA Women’s Health Centre“, AXA policyholders can enjoy exclusive benefits, including cashless services for eligible medical treatments and up to 30% discounts on designated health check-ups. For more details, please visit “Emma By AXA”, our all-in-one insurance & health services mobile application.

About AXA Hong Kong and Macau

AXA Hong Kong and Macau is a member of the AXA Group, a leading global insurer with presence in 50 markets and serving 94 million customers worldwide. Our purpose is to act for human progress by protecting what matters.

As one of the most diversified insurers in Hong Kong, we offer integrated solutions across Life, Health and General Insurance. We are the largest General Insurance provider and a major Health and Employee Benefits provider. Our aim is to not only be the insurer to provide comprehensive protection to our customers, but also a holistic partner to the individuals, businesses and community we serve. At the core of our service commitment is continuous product & service innovation and customer experience enrichment, which is achieved through actively listening to our customers’ needs and leveraging and investing in technology and digital transformation.

We embrace our responsibility to be a driving force against climate change and a force for good to create shared value for our community. We are proud to be the first to address the importance of mental health through different products and services and thought leading iconic research. Our overall Sustainability Strategy, with emphasis on climate strategy and biodiversity commitment, is developed based on TCFD recommendations. We are committed to integrating environmental, social and governance factors across our business and strive to contribute to a sustainable future through 3 distinct roles – as an investor, insurer and an exemplary company.

About Chiron Medical Group

Chiron Medical Group (“Chiron Medical”) adheres to a patient-centered approach and the establishment of trustworthy medical care. Our mission is to provide comprehensive medical services that encompass prevention, diagnosis, treatment, and ongoing management of various health conditions, offering patients a one-stop healthcare solution.

We possess an exceptional team of specialised medical professionals and advanced technologies. By combining effective communication with our patients, we provide personalised medical care to ensure that patients have the best experience throughout the consultation, treatment process, and the establishment of a healthy lifestyle. We strive to become their trusted medical partner.

About FemWell

FemWell, a female health brand owned by Chiron Medical Group, is established to provide a holistic caring platform for the Women’s health nowadays. With a multi-disciplinary team of female experts to focus on all aspects of women’s wellness and the all-rounded “Illness treatment” to “Wellness management” concept, FemWell brings the idea of the optimal health for women and works together towards a prosperous life.

The launch of the Women’s Health Center is the first step in FemWell’s promotional campaign.  Moving forward, FemWell is committed to delivering continuous  health information,  conducting workshops on physical and mental well-being, and offering personalised treatment plans. Our ultimate goal is to empower women to prioritise their personal health and address their overall physical and mental well-being.

THIS PRESS RELEASE IS AVAILABLE ON AXA, CHIRON MEDICAL AND FEMWELL WEBSITE: AXA.COM.HK、Chiron.care、FemWell.com

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed or implied in the forward-looking statements. Please refer to Part 4 – “Risk factors and risk management” of AXA’s Universal Registration Document for the year ended December 31, 2019, for a description of certain important factors, risks and uncertainties that may affect AXA’s business, and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as part of applicable regulatory or legal obligations.

Source

DUBLIN, March 8, 2024 /PRNewswire/ — Avia Solutions Group, the world’s largest ACMI (Aircraft, Crew, Maintenance, and Insurance) provider with a fleet of 199 aircraft, has finalized the acquisition of the Australian airline Skytrans. The airline, which holds a fleet of 13 regional aircraft, specializes in Regular Public Transport (RPT) as well as charter operations.

With the acquisition of Skytrans, the group secures an Australian Air Operator Certificate (AOC), paving the way for both passenger and cargo flight operations. The move will, moreover, allow the group to access the lucrative domestic aviation market in Australia, which, according to projections published in the Australian Aviation Network review of 2023, is set to exceed pre-COVID levels in 2024.

This development is part of the group’s growth strategy within the Asia-Pacific region. Expansion in the region provides valuable leverage to counterbalance the reduced seasonal demand in Europe by shifting aircraft between counter-seasonal regions. The obtained AOC brings the total number of air operator certificates held by the group to 12.

“This acquisition is part of our larger strategy, which is aimed at limiting the impact of seasonality, whilst giving us access to new growing markets in Asia-Pacific and further afield. By the end of the year, we aim to establish or acquire 7 additional airlines, with countries like Thailand, Philippines, Malaysia, and Indonesia firmly on our radar,” says Jonas Janukenas, CEO of Avia Solutions Group.

According to the newly appointed Managing Director of Skytrans, Gytis Gumuliauskas, while the company’s current activities will be continued, the main goal is to extensively develop ACMI and wet lease operations:

“Passenger operations will be our main area of focus, with cargo being an area we’re willing to explore and develop in 2024 and beyond. To achieve these goals, we have plans of expanding the fleet with A319 aircraft for passenger and with A321F for cargo transportation.”

Irish-based Avia Solutions Group is the parent company to SmartLynx Airlines, Avion Express, AirExplore, KlasJet, Magma Aviation, and more, operating worldwide. The group also comprises a leading global provider of MRO services, FL Technics, with 100 line maintenance stations worldwide and maintenance hangars in Lithuania, Indonesia, and the United Kingdom. Furthermore, Avia Solutions Group also operates the largest independent pilot training organization, BAA Training, with schools in Spain, France, Lithuania, and Vietnam.

About Avia Solutions Group:

Avia Solutions Group, the world’s largest ACMI provider (Aircraft, Crew, Maintenance, and Insurance), operates a fleet of 199 aircraft and is the parent company to over 100 subsidiaries including SmartLynx Airlines, Avion Express, Bluebird Nordic, BBN Indonesia Airlines, and KlasJet. The group also provides a range of aviation services: MRO (Maintenance, Repair, and Overhaul), pilot and crew training, ground handling, as well as a variety of associated services. Supported by 11,700 highly skilled aviation professionals.

For more information: www.aviasg.com   

Source

Recognized for Marketing Excellence and Received TikTok for Business Overseas Marketing Awards

SHANGHAI, March 8, 2024 /PRNewswire/ — Infinix, a trendy tech brand crafted for young consumers, is thrilled to announce its exceptional performance in 2023. According to IDC’s Worldwide Quarterly Mobile Phone Tracker, Infinix has achieved a remarkable milestone in year-on-year increase in units in smartphone shipments, surpassing all other global smartphone brands with an astounding accomplishment of over 13 million units increase. This translates to an impressive growth rate of 64.1% compared to 2022.

Tony Zhao, General Manager of Infinix, proudly attributes the company’s achievements to a multifaceted marketing approach, technological innovation, and strategic collaborations with key industry players, such as TikTok. By utilizing the platform, Infinix successfully connects with its target users, empowering them to exceed their limitations and unlock their full potential.

“Infinix focuses on catering to youth preferences, providing tailored-made technological innovations, and recognizing the pivotal role of strategic partnerships. By leveraging TikTok as a creative platform, Infinix effectively reaches our target users, enabling them to conquer their limits and become the best versions of themselves.” Tony Zhao.

Infinix Receives TikTok for Business Overseas Marketing Award

Infinix’s marketing prowess recently earned them TikTok for Business’s Overseas Marketing Award for being the “Innovator”, recognizing their standout efforts in the international markets. This prestigious award celebrates companies making waves globally, inspiring others with innovative marketing practices. Infinix’s success stems from its strategic approach, utilizing TikTok’s platform to its fullest. By embracing various gameplay options and collaborating with influencers, Infinix has effectively grown its brand from awareness to tangible results, showcasing the power of creative marketing.

Since its inception in 2013, Infinix has established a strong presence in overseas markets. The brand’s engagement with users through compelling content and its sales success on e-commerce platforms highlight a symbiotic relationship. Campaigns like Infinix Super Brand Day and the “Capture Your Own Story” Vlog Contest have been key successes, further cementing Infinix’s position as an innovative leader in the tech industry.

Game-Changing Innovations Unveiled at CES & MWC 2024

Infinix continued to make waves in the industry with its game-changing innovations showcased at CES and MWC. At CES, Infinix amazed the audience with the introduction of Infinix AirCharge, a revolutionary wireless charging technology that eliminates the need for cords or charging pads. This breakthrough innovation provides a hassle-free way to power up the devices. Additionally, Infinix unveiled the Extreme-Temp Battery, addressing the challenges of extreme temperatures to ensure smooth device performance in any environment. Infinix also introduced Infinix E-Color Shift, the industry’s first customizable display panel for smartphone appearances. At MWC, Infinix turned heads with their flagship mobile gaming concept, promising a new era of mobile gaming with top-notch performance and graphics. As 2024 unfolds, Infinix is poised to lead the way with more groundbreaking innovations, setting the stage for an exciting future.

For more details, visit: http://www.infinixmobility.com, Facebook, Instagram, YouTube & X.

About Infinix

Infinix Mobility is a rapidly emerging technology brand that designs, manufactures and markets an expanding portfolio of smart devices worldwide under the Infinix brand, which was founded in 2013. Targeting today’s youth with first in class technology, Infinix creates trendy, powerful and attainably priced smart devices that bring the latest technology on the market to users around the world at a time when they need it at a price that they want.

Source

HANGZHOU, China, March 8, 2024 /PRNewswire/ — On the afternoon of March 7, 2024, China National Silk Museum held the opening ceremony of the “Special Exhibition of Ritual Utensils, Musical Instruments and Costumes of the Kong (Confucius) Family Mansion”. And in “the Night of Rituals and Music”, a music feast was brought by the Xiaoshao Music Troupe of the Confucius Museum. They played with dozens of musical instruments such as set of bells, chime stones, qin, se and chi, restored with reference to excavated musical instruments and artifacts. The performance featured such pieces as “The Book of Poetry”, “Autumn Thoughts on the Dressing Table”, “Phoenix Seeking His Mate”, and “A Moonlit Night on the Spring River”, as well as the dance from the ancient rituals.

Confucius, a renowned philosopher, politician and educator in ancient China, was instrumental in promoting the rich traditions of ritual and music from the pre-Qin Period. Revered as the “Sacred Model Teacher for Ten Thousand Generations” by Chinese emperors, his system of belief involving philosophy, politics and ethics (subsequently known as Confucianism) has exerted profound influence on Chinese culture, including sartorial etiquette.

Located in his birthplace, Qufu City of Shandong Province, China, the Confucius Museum, which houses artifacts from the Confucius Mansion (also known as the Kong Family Mansion) housing the male direct descendants of Confucius, has a leading collection of over 100,000 collections; among them the ten ceremonial utensils of the Shang and Zhou dynasties. Within this remarkable collection, the series of Confucius portraits, crafted over various historical periods, and the authentic Ming and Qing dynasty garments and headwear stand out as particularly renowned treasures.

In a collaborative effort to illuminate the sage’s teachings, the China National Silk Museum and Confucius Museum are proud to present an exhibition in Hangzhou. This event will celebrate the legacy of Confucian virtues, the sophistication of ancient ceremonial practices, and the splendor of traditional Chinese fashion. The exhibition will feature nearly a hundred ceremonial instruments used in Confucius worship, originating from the Confucius Mansion collection, as well as Ming, Qing, and Republic-period garments and headpieces passed down through Confucius‘ lineage.

The exhibition will last till May 26, 2024. A series of events will be held during this period.

Source